Lin Chang

List of Publications by Citations

193 papers	10,645 citations	58 h-index	100 g-index
240 ext. papers	12,541 ext. citations	5.2 avg, IF	6.28 L-index

#	Paper	IF	Citations
193	Bowel Disorders. *Gastroenterology*, **2016**,	13.3	1260
192	V. Stress and irritable bowel syndrome. *American Journal of Physiology - Renal Physiology*, **2001**, 280, G519-24	5.1	306
191	Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. *Gastroenterology*, **2006**, 130, 1435-46	13.3	263
190	Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. *Psychosomatic Medicine*, **2001**, 63, 365-75	3.7	254
189	Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. *Gastroenterology*, **2016**,	13.3	242
188	Sex-related differences in IBS patients: central processing of visceral stimuli. *Gastroenterology*, **2003**, 124, 1738-47	13.3	238
187	Review article: epidemiology and quality of life in functional gastrointestinal disorders. *Alimentary Pharmacology and Therapeutics*, **2004**, 20 Suppl 7, 31-9	6.1	234
186	Gender differences in irritable bowel syndrome. *Gastroenterology*, **2002**, 123, 1686-701	13.3	233
185	Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. *Pain*, **2005**, 115, 398-409	8	219
184	A comparison of visceral and somatic pain processing in the human brainstem using functional magnetic resonance imaging. *Journal of Neuroscience*, **2005**, 25, 7333-41	6.6	203
183	Association between early adverse life events and irritable bowel syndrome. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 385-90.e1-3	6.9	194
182	Gender-related differences in IBS symptoms. *American Journal of Gastroenterology*, **2001**, 96, 2184-93	0.7	172
181	Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. *American Journal of Gastroenterology*, **2003**, 98, 135-43	0.7	166
180	The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. *Psychosomatic Medicine*, **2007**, 69, 89-98	3.7	163
179	Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. *Gastroenterology*, **2006**, 131, 352-65	13.3	155
178	Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. *Gastroenterology*, **2009**, 137, 1954-62	13.3	147
177	The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. *Gastroenterology*, **2011**, 140, 761-5	13.3	144

176	Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. *Pain*, **2000**, 84, 297-307	8	144
175	Gender differences in regional brain response to visceral pressure in IBS patients. *European Journal of Pain*, **2000**, 4, 157-72	3.7	142
174	Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. *American Journal of Gastroenterology*, **2001**, 96, 3341-7	0.7	139
173	A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. *American Journal of Gastroenterology*, **2011**, 106, 1803-12	0.7	131
172	Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. *Archives of Internal Medicine*, **2004**, 164, 1773-80		131
171	Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. *American Journal of Gastroenterology*, **2006**, 101, 1069-79	0.7	127
170	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. *American Journal of Gastroenterology*, **2014**, 109, 1804-14	0.7	123
169	Functional GI disorders: from animal models to drug development. *Gut*, **2008**, 57, 384-404	19.2	121
168	A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. *Gut*, **2005**, 54, 1707-13	19.2	119
167	Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. *Gastroenterology*, **2002**, 123, 969-77	13.3	119
166	Prevalence of irritable bowel syndrome among university students: the roles of worry, neuroticism, anxiety sensitivity and visceral anxiety. *Journal of Psychosomatic Research*, **2003**, 55, 501-5	4.1	116
165	Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. *American Journal of Gastroenterology*, **2010**, 105, 848-58	0.7	112
164	The effect of life stress on symptoms of heartburn. *Psychosomatic Medicine*, **2004**, 66, 426-34	3.7	111
163	Cortical processing of visceral and somatic stimulation: differentiating pain intensity from unpleasantness. *Neuroscience*, **2005**, 133, 533-42	3.9	110
162	Sex specific alterations in autonomic function among patients with irritable bowel syndrome. *Gut*, **2005**, 54, 1396-401	19.2	108
161	Chronic constipation. *Nature Reviews Disease Primers*, **2017**, 3, 17095	51.1	106
160	Serum and colonic mucosal immune markers in irritable bowel syndrome. *American Journal of Gastroenterology*, **2012**, 107, 262-72	0.7	104
159	A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. *American Journal of Gastroenterology*, **2005**, 100, 115-23	0.7	100

158	Preoperative versus postoperative endoscopic retrograde cholangiopancreatography in mild to moderate gallstone pancreatitis: a prospective randomized trial. *Annals of Surgery*, **2000**, 231, 82-7	7.8	99
157	Predictors of patient-assessed illness severity in irritable bowel syndrome. *American Journal of Gastroenterology*, **2008**, 103, 2536-43	0.7	94
156	Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. *American Journal of Gastroenterology*, **2005**, 100, 896-904	0.7	92
155	Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome?. *Gender Medicine*, **2009**, 6 Suppl 2, 152-67		91
154	Symptom differences in moderate to severe IBS patients based on predominant bowel habit. *American Journal of Gastroenterology*, **1999**, 94, 2929-35	0.7	91
153	American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. *Gastroenterology*, **2014**, 147, 1149-72.e2	13.3	90
152	MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. *Gastroenterology*, **2015**, 149, 981-92.e11	13.3	90
151	Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. *American Journal of Gastroenterology*, **2003**, 98, 1354-61	0.7	89
150	A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. *Digestive Diseases and Sciences*, **2009**, 54, 1532-41	4	83
149	Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. *Gut*, **2018**, 67, 263-270	19.2	79
148	Sex-based differences in gastrointestinal pain. *European Journal of Pain*, **2004**, 8, 451-63	3.7	78
147	Diagnosis and management of IBS. *Nature Reviews Gastroenterology and Hepatology*, **2010**, 7, 565-81	24.2	77
146	Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?. *American Journal of Gastroenterology*, **2008**, 103, 2972-6	0.7	77
145	Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2006**, 291, R277-84	3.2	77
144	Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. *American Journal of Gastroenterology*, **2002**, 97, 2803-11	0.7	74
143	Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. *American Journal of Gastroenterology*, **2010**, 105, 866-75	0.7	70
142	Impact of sex and gender on irritable bowel syndrome. *Biological Research for Nursing*, **2003**, 5, 56-65	2.6	69
141	Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 1161-8	6.1	67

140	Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. *American Journal of Gastroenterology*, **2000**, 95, 152-6	0.7	66
139	Basic pathophysiologic mechanisms in irritable bowel syndrome. *Digestive Diseases*, **2001**, 19, 212-8	3.2	65
138	Gallstone pancreatitis: a prospective study on the incidence of cholangitis and clinical predictors of retained common bile duct stones. *American Journal of Gastroenterology*, **1998**, 93, 527-31	0.7	65
137	Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. *American Journal of Gastroenterology*, **2012**, 107, 451-9	0.7	63
136	Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome?. *Gastrointestinal Endoscopy*, **2005**, 62, 892-9	5.2	61
135	Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity. *Neurogastroenterology and Motility*, **2016**, 28, 1252-60	4	58
134	Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. *Gastroenterology*, **2008**, 135, 1877-91	13.3	57
133	Attentional modulation of visceral and somatic pain. *Neurogastroenterology and Motility*, **2007**, 19, 569-77	4	56
132	Enhanced preattentive central nervous system reactivity in irritable bowel syndrome. *American Journal of Gastroenterology*, **2002**, 97, 2791-7	0.7	50
131	Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. *American Journal of Gastroenterology*, **2009**, 104, 1984-91	0.7	49
130	Brain responses to visceral and somatic stimuli in irritable bowel syndrome: a central nervous system disorder?. *Gastroenterology Clinics of North America*, **2005**, 34, 271-9	4.4	49
129	Impact of irritable bowel syndrome on patients' lives: development and psychometric documentation of a disease-specific measure for use in clinical trials. *European Journal of Gastroenterology and Hepatology*, **2005**, 17, 411-20	2.2	47
128	Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. *BMJ Open Gastroenterology*, **2017**, 4, e000134	3.9	46
127	A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. *Therapeutic Advances in Gastroenterology*, **2013**, 6, 344-57	4.7	39
126	Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. *Gastroenterology Clinics of North America*, **2007**, 36, 665-85, x	4.4	39
125	New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments. *Current Gastroenterology Reports*, **2005**, 7, 272-9	5	38
124	Expression of the Bitter Taste Receptor, T2R38, in Enteroendocrine Cells of the Colonic Mucosa of Overweight/Obese vs. Lean Subjects. *PLoS ONE*, **2016**, 11, e0147468	3.7	38
123	Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1673-1676	6.9	37

122	The effect of sex and irritable bowel syndrome on HPA axis response and peripheral glucocorticoid receptor expression. *Psychoneuroendocrinology*, **2016**, 69, 67-76	5	37
121	Increased acoustic startle responses in IBS patients during abdominal and nonabdominal threat. *Psychosomatic Medicine*, **2008**, 70, 920-7	3.7	35
120	The association of functional gastrointestinal disorders and fibromyalgia. *The European Journal of Surgery*, **1998**, 32-6		35
119	Early adverse life events are associated with altered brain network architecture in a sex- dependent manner. *Neurobiology of Stress*, **2017**, 7, 16-26	7.6	33
118	Functional Bowel Disorders: A Roadmap to Guide the Next Generation of Research. *Gastroenterology*, **2018**, 154, 723-735	13.3	33
117	GERD symptoms in the general population: prevalence and severity versus care-seeking patients. *Digestive Diseases and Sciences*, **2014**, 59, 2488-96	4	33
116	Activation of pruritogenic TGR5, MrgprA3, and MrgprC11 on colon-innervating afferents induces visceral hypersensitivity. *JCI Insight*, **2019**, 4,	9.9	33
115	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. *Gastroenterology*, **2018**, 155, 168-179	13.3	31
114	Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. *Therapeutic Advances in Gastroenterology*, **2017**, 10, 253-275	4.7	31
113	Differences in gastrointestinal symptoms according to gender in Rome II positive IBS and dyspepsia in a Latin American population. *American Journal of Gastroenterology*, **2010**, 105, 925-32	0.7	31
112	Racial differences in the impact of irritable bowel syndrome on health-related quality of life. *Journal of Clinical Gastroenterology*, **2004**, 38, 782-9	3	31
111	Morphological brain measures of cortico-limbic inhibition related to resilience. *Journal of Neuroscience Research*, **2017**, 95, 1760-1775	4.4	29
110	Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome. *American Journal of Gastroenterology*, **2017**, 112, 892-899	0.7	28
109	Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. *Digestive Diseases and Sciences*, **2017**, 62, 1186-1192	4	27
108	Understanding gastrointestinal distress: a framework for clinical practice. *American Journal of Gastroenterology*, **2011**, 106, 380-5	0.7	27
107	Diagnosis and treatment of irritable bowel syndrome: state of the art. *Current Gastroenterology Reports*, **2005**, 7, 249-56	5	27
106	Irritable bowel syndrome patients have SCN5A channelopathies that lead to decreased Na1.5 current and mechanosensitivity. *American Journal of Physiology - Renal Physiology*, **2018**, 314, G494-G503	5.1	27
105	Diminished expression of CRHR2 in human colon cancer promotes tumor growth and EMT via persistent IL-6/Stat3 signaling. *Cellular and Molecular Gastroenterology and Hepatology*, **2015**, 1, 610-630	7.9	26

104	Computer-generated vs. physician-documented history of present illness (HPI): results of a blinded comparison. *American Journal of Gastroenterology*, **2015**, 110, 170-9	0.7	25
103	Autonomic response to a visceral stressor is dysregulated in irritable bowel syndrome and correlates with duration of disease. *Neurogastroenterology and Motility*, **2013**, 25, e650-9	4	25
102	Resilience is decreased in irritable bowel syndrome and associated with symptoms and cortisol response. *Neurogastroenterology and Motility*, **2018**, 30, e13155	4	24
101	Diagnostic approach to the patient with irritable bowel syndrome. *American Journal of Medicine*, **1999**, 107, 20S-26S	2.4	24
100	Genome-wide DNA methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome. *Neurogastroenterology and Motility*, **2016**, 28, 410-22	4	24
99	Identification of a functional TPH1 polymorphism associated with irritable bowel syndrome bowel habit subtypes. *American Journal of Gastroenterology*, **2013**, 108, 1766-74	0.7	23
98	Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria. *American Journal of Gastroenterology*, **2011**, 106, 1299-307	0.7	22
97	Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 1114-1122	6.1	22
96	Interactions of early adversity with stress-related gene polymorphisms impact regional brain structure in females. *Brain Structure and Function*, **2016**, 221, 1667-79	4	21
95	The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 1302-12	6.1	21
94	Is there a difference between abdominal pain and discomfort in moderate to severe IBS patients?. *American Journal of Gastroenterology*, **2002**, 97, 3131-8	0.7	21
93	Towards an integrative model of irritable bowel syndrome. *Progress in Brain Research*, **2000**, 122, 413-23	2.9	20
92	A double blind parallel group pilot study of the effects of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. *Gastroenterology*, **2000**, 118, A846	13.3	20
91	Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis. *Arthritis Care and Research*, **2014**, 66, 1725-30	4.7	19
90	miR-24 Is Elevated in Ulcerative Colitis Patients and Regulates Intestinal Epithelial Barrier Function. *American Journal of Pathology*, **2019**, 189, 1763-1774	5.8	18
89	Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID. *American Journal of Gastroenterology*, **2010**, 105, 722-30	0.7	18
88	Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database. *American Journal of Gastroenterology*, **2014**, 109, 234-48	0.7	17
87	Gene expression profiles in peripheral blood mononuclear cells correlate with salience network activity in chronic visceral pain: A pilot study. *Neurogastroenterology and Motility*, **2017**, 29, e13027	4	16

86	□-opioid receptor, □endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients. *Neurogastroenterology and Motility*, **2019**, 31, e13688	4	15
85	Predictors of Health-related Quality of Life in Irritable Bowel Syndrome Patients Compared With Healthy Individuals. *Journal of Clinical Gastroenterology*, **2019**, 53, e142-e149	3	15
84	Computer versus physician identification of gastrointestinal alarm features. *International Journal of Medical Informatics*, **2015**, 84, 1111-7	5.3	14
83	Emerging pharmacological therapies for the irritable bowel syndrome. *Gastroenterology Clinics of North America*, **2011**, 40, 223-43	4.4	14
82	New treatments for irritable bowel syndrome in women. *Women's Health*, **2008**, 4, 605-22; quiz 623	3	14
81	Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population. *Neurogastroenterology and Motility*, **2017**, 29, e13003	4	13
80	Catecholaminergic Gene Polymorphisms Are Associated with GI Symptoms and Morphological Brain Changes in Irritable Bowel Syndrome. *PLoS ONE*, **2015**, 10, e0135910	3.7	13
79	Risk and Protective Factors Related to Early Adverse Life Events in Irritable Bowel Syndrome. *Journal of Clinical Gastroenterology*, **2020**, 54, 63-69	3	13
78	Sex-Related Differences in GI Disorders. *Handbook of Experimental Pharmacology*, **2017**, 239, 177-192	3.2	12
77	Novel techniques to study visceral hypersensitivity in irritable bowel syndrome. *Current Gastroenterology Reports*, **2008**, 10, 369-78	5	12
76	Admission factors can predict the need for ICU monitoring in gallstone pancreatitis. *American Surgeon*, **1996**, 62, 815-9	0.8	12
75	Negative Events During Adulthood Are Associated With Symptom Severity and Altered Stress Response in Patients With Irritable Bowel Syndrome. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2245-2252	6.9	11
74	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. *Nature Genetics*, **2021**, 53, 1543-1552	36.3	11
73	Sigmoid colon mucosal gene expression supports alterations of neuronal signaling in irritable bowel syndrome with constipation. *American Journal of Physiology - Renal Physiology*, **2018**, 315, G140-G157	3.1	10
72	A cross-cultural investigation of attachment style, catastrophizing, negative pain beliefs, and symptom severity in irritable bowel syndrome. *Neurogastroenterology and Motility*, **2015**, 27, 490-500	4	10
71	Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. *Therapeutic Advances in Gastroenterology*, **2010**, 3, 291-305	4.7	10
70	Epigenetic Mechanisms in Irritable Bowel Syndrome. *Frontiers in Psychiatry*, **2020**, 11, 805	5	10
69	Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials. *Therapeutic Advances in Gastroenterology*, **2019**, 12, 1756284819841290	4.7	9

68	Clostridial bacteremia: implications for the surgeon. *American Surgeon*, **1991**, 57, 388-93	0.8	9
67	Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. *Therapeutic Advances in Gastroenterology*, **2017**, 10, 689-699	4.7	8
66	Does mind-body medicine have a role in gastroenterology?. *Current Opinion in Gastroenterology*, **1997**, 13, 1-4	3	8
65	Plasma Corticotropin-Releasing Factor Receptors and B7-2+ Extracellular Vesicles in Blood Correlate with Irritable Bowel Syndrome Disease Severity. *Cells*, **2019**, 8,	7.9	8
64	Early computed tomography is rarely necessary in gallstone pancreatitis. *American Surgeon*, **1997**, 63, 904-7	0.8	8
63	313 Effects of Rifaximin on Urgency, Bloating, and Abdominal Pain in Patients With IBS-D: A Randomized, Controlled, Repeat Treatment Study. *Gastroenterology*, **2015**, 148, S-69	13.3	7
62	Irritable Bowel Syndrome. *Current Treatment Options in Gastroenterology*, **2002**, 5, 267-278	2.5	7
61	Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis. *American Journal of Gastroenterology*, **2021**, 116, 748-757	0.7	7
60	The Role of Resilience in Irritable Bowel Syndrome, Other Chronic Gastrointestinal Conditions, and the General Population. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 2541-2550.e1	6.9	7
59	Analysis of brain networks and fecal metabolites reveals brain-gut alterations in premenopausal females with irritable bowel syndrome. *Translational Psychiatry*, **2020**, 10, 367	8.6	7
58	The Colonic Mucosal MicroRNAs, MicroRNA-219a-5p, and MicroRNA-338-3p Are Downregulated in Irritable Bowel Syndrome and Are Associated With Barrier Function and MAPK Signaling. *Gastroenterology*, **2021**, 160, 2409-2422.e19	13.3	7
57	Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response. *Psychoneuroendocrinology*, **2016**, 73, 133-141	5	7
56	Evolving pathophysiological model of functional gastrointestinal disorders: implications for treatment. *The European Journal of Surgery Supplement: = Acta Chirurgica Supplement*, **2002**, 3-9		7
55	Postmenopausal women with irritable bowel syndrome (IBS) have more severe symptoms than premenopausal women with IBS. *Neurogastroenterology and Motility*, **2020**, 32, e13913	4	6
54	Functional Bowel Disorders. *Gastroenterology*, **2018**, 155, 1-4	13.3	6
53	Using the Rome IV Criteria to Help Manage the Complex IBS Patient. *American Journal of Gastroenterology*, **2018**, 113, 453-456	0.7	6
52	Evidence for decreased activation of central fear circuits by expected aversive visceral stimuli in IBS patients. *Gastroenterology*, **2000**, 118, A137	13.3	6
51	An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium. *Gastroenterology and Hepatology*, **2010**, 6, 1-12	0.7	6

50	A Review of the Evidence and Recommendations on Communication Skills and the Patient-Provider Relationship: A Rome Foundation Working Team Report. *Gastroenterology*, **2021**, 161, 1670-1688.e7	13.3	6
49	Approaches to the Modulation of Abdominal Pain. *Canadian Journal of Gastroenterology & Hepatology*, **1999**, 13, 66A-70A		5
48	Increasing Rates of Opioid Prescriptions for Gastrointestinal Diseases in the United States. *American Journal of Gastroenterology*, **2021**, 116, 796-807	0.7	5
47	Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. *American Journal of Gastroenterology*, **2021**, 116, 1601-1611	0.7	5
46	Effect of Exclusion Diets on Symptom Severity and the Gut Microbiota in Patients With Irritable Bowel Syndrome. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	5
45	Importance of trauma-related fear in patients with irritable bowel syndrome and early adverse life events. *Neurogastroenterology and Motility*, **2020**, 32, e13896	4	4
44	1090 - Epigenetic Changes in Blood Cells and Colonic Mucosa are Associated with Irritable Bowel Syndrome (IBS). *Gastroenterology*, **2018**, 154, S-214	13.3	4
43	Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome. *Women's Health*, **2007**, 3, 15-27	3	4
42	Brain-gut interactions: implications for newer therapy. *The European Journal of Surgery*, **1998**, 50-5		4
41	Opioid Prescription Patterns Among US Gastroenterologists From 2013 to 2017. *Gastroenterology*, **2020**, 158, 776-779.e2	13.3	4
40	Mo1616 Resilience Is Decreased in Irritable Bowel Syndrome (IBS) and Associated With Poorer Quality of Life and Greater Symptom Severity. *Gastroenterology*, **2016**, 150, S731	13.3	4
39	2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome. *Cellular and Molecular Gastroenterology and Hepatology*, **2016**, 2, 394-399.e2	7.9	4
38	Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study. *Digestive Diseases and Sciences*, **2021**, 66, 1836-1844	4	4
37	Small intestinal immunopathology and GI-associated antibody formation in hereditary alpha-tryptasemia. *Journal of Allergy and Clinical Immunology*, **2021**, 148, 813-821.e7	11.5	4
36	Dysregulation of the Long-Noncoding RNA, Ghrlos, in Irritable Bowel Syndrome. *Gastroenterology*, **2017**, 152, S722	13.3	3
35	T1026 Measuring IBS Patient Reported Outcomes with a Single Item Numeric Rating Scale: Results from the PROOF Cohort. *Gastroenterology*, **2008**, 134, A-467	13.3	3
34	Irritable bowel syndrome: new and emerging therapies. *Current Opinion in Internal Medicine*, **2006**, 22, 128-35		3
33	The role of gender and bowel habit predominance on visceral perception in IBS. *Gastroenterology*, **2001**, 120, A755	13.3	3

32	Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System. *American Journal of Gastroenterology*, **2021**, 116, 1929-1937	0.7	3
31	2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome. *Clinical Gastroenterology and Hepatology*, **2016**, 14, e77-86	6.9	3
30	Latest Insights on the Pathogenesis of Irritable Bowel Syndrome. *Gastroenterology Clinics of North America*, **2021**, 50, 505-522	4.4	3
29	Increased Sleep Disturbances in Irritable Bowel Syndrome (IBS) Patients is Associated with Greater Symptom Severity and Decreased Quality Of Life. *Gastroenterology*, **2017**, 152, S716	13.3	2
28	366 Guanylate Cyclase-C Expression Is Down-Regulated in Colonic Biopsies From Female Irritable Bowel Syndrome Patients With Constipation. *Gastroenterology*, **2016**, 150, S81-S82	13.3	2
27	Rifaximin Repeat Treatment in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Produced No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. *American Journal of Gastroenterology*, **2015**, 110, S761	0.7	2
26	Do Patients Understand the Bristol Stool Scale? Results of Cognitive De-Briefing of IBS Patients. *Gastroenterology*, **2011**, 140, S-615	13.3	2
25	Response to Drs Trivedi and Ward. *American Journal of Gastroenterology*, **2012**, 107, 140-141	0.7	2
24	Clinical determinants of health-related quality of life in irritable bowel syndrome. *Gastroenterology*, **2003**, 124, A398	13.3	2
23	Differences in rectal mechanoelastic properties according to predominant bowel habit in IBS patients. *Gastroenterology*, **2000**, 118, A667	13.3	2
22	Evidence for selective effect of the 5HT3 antagonist alosetron on amygdala and hippocampal activation in IBS patients. *Gastroenterology*, **2000**, 118, A81	13.3	2
21	The effect of the 5-HT3 receptor antagonist alosetron on regional brain activation in IBS patients is not dependent on activation of nociceptive visceral afferents: A H215O PET study. *Gastroenterology*, **2001**, 120, A67	13.3	2
20	Do Proton Pump Inhibitors (PPIs) Predispose to the Development of SIBO in IBS versus Non-IBS Patients?. *American Journal of Gastroenterology*, **2009**, 104, S103-S104	0.7	2
19	Guanylate Cyclase-C Receptor and Ligand Expression in Colonic Mucosa in Chronic Constipation. *American Journal of Gastroenterology*, **2014**, 109, S540	0.7	2
18	Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare. *Inflammatory Bowel Diseases*, **2021**, 27, 1576-1584	4.5	2
17	The Gut Microbiome and Digestive Health - A New Frontier. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 215-217	6.9	2
16	Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis. *Digestive Diseases and Sciences*, **2021**, 66, 4140-4148	4	2
15	Is IBS a Predictor of SIBO as Identified by Hydrogen/Methane Breath Testing?. *American Journal of Gastroenterology*, **2009**, 104, S110	0.7	1

14	An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D. *Gastroenterology and Hepatology*, **2013**, 9, 1-24	0.7	1
13	Gender-Related Differences in Functional Bowel Disorders **2004**, 438-445		1
12	Cytokine Levels and Symptoms Among Women with Irritable Bowel Syndrome: Considering the Role of Hormonal Contraceptive Use. *Biological Research for Nursing*, **2021**, 23, 171-179	2.6	1
11	How to Approach a Patient with Difficult-to-Treat IBS. *Gastroenterology*, **2021**, 161, 1092-1098.e3	13.3	1
10	Obesity is associated with a distinct brain-gut microbiome signature that connects Prevotella and Bacteroides to the brain's reward center.. *Gut Microbes*, **2022**, 14, 2051999	8.8	1
9	A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2021**, 54, 281-291	6.1	0
8	The visceral sensitivity index: A novel tool for measuring GI-symptom-specific anxiety in inflammatory bowel disease.. *Neurogastroenterology and Motility*, **2022**, e14384	4	0
7	Treatment of bloating and distension □role of probiotics: authors□reply. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 581-583	6.1	
6	Comment on □Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia□L. Chang et al., PAIN 84 (2000) 297□307. *Pain*, **2001**, 91, 404-405	8	
5	MicroRNA targeting for the therapy of colitis-associated colon cancer.. *Journal of Clinical Oncology*, **2015**, 33, 571-571	2.2	
4	Reply. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	
3	487 Use of Central Neuromodulators by Gastroenterologists in the Treatment of IBS: A Pilot Survey. *American Journal of Gastroenterology*, **2019**, 114, S282-S282	0.7	
2	489 Opioid and Neuromodulator Prescription Patterns Among U.S. Gastroenterologists. *American Journal of Gastroenterology*, **2019**, 114, S283-S283	0.7	
1	Reply to Letter to Editor.. *Clinical Gastroenterology and Hepatology*, **2022**,	6.9	